• No se han encontrado resultados

Análisis de la investigación independiente en ensayos clínicos con medicamentos en el Hospital Universitari Vall d’Hebron

N/A
N/A
Protected

Academic year: 2017

Share "Análisis de la investigación independiente en ensayos clínicos con medicamentos en el Hospital Universitari Vall d’Hebron"

Copied!
215
0
0

Texto completo

Loading

Figure

Tabla 1: Motivos para la no aprobación del CEIC de los ensayos duplicados
Figura 2: Flujo de selección  de los ensayos clínicos con medicamentos objeto del estudio
Tabla 2: Motivos para la cancelación de la evaluación del CEIC
Tabla 4: Tiempo desde la presentación al CEIC del HUVH hasta la obtención del dictamen según la resolución del CEIC*
+7

Referencias

Documento similar

In the context of academic research, our group devel- oped and sponsored the RAVELLO trial, a phase III, international, double-blind, placebo-controlled, inves- tigator-initiated

Methods: This single-center, assessor-blind, parallel-group, randomised clinical trial (RCT) aims to investigate the efficacy of MCT for improving insight (primary outcome),

The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled,

Effectiveness of Day Hospital Mentalization-Based Treatment for Patients with Severe Borderline Personality Disorder: A Matched Control Study.. Treatment of Borderline

BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving

Sensitivity/ pain response was assessed by using the Numerical 0-10 Visual Analogue Scale (VAS) (17). Pre treatment sensitivity was evaluated on the by the first

In this first report we describe data from the cross-sectional phase of the study, which aimed at evaluating: (i) the proportion of patients with controlled, partly controlled

OPUS, Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer; PEAK, Panitumumab Efficacy in Combination With mFOLFOX6 Against Bevacizumab Plus mFOLOFOX6